Our study was the first one to use envafolimab, the first subcutaneous single-domain anti–PD-L1 antibody,7 to treat platinum-resistant recurrent ovarian cancer in combination with lenvatinib and etoposide, showing an ORR of 44.4%, a DCR of 83.3%, and a median PFS of 10.2 months, indicating that the “home-stay” regimen had effective antitumor activity against platinum-resistant recurrent ovarian cancer. This evidence concerns the gene CD274 and ovarian cancer.